SCHEMBL5886777

SCHEMBL5886777

Cc1nc(N2CCN(c3ccccc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NCc2cccnc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.46
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
PTGER1 P34995 1/20 0.44
LMNA P02545 3/20 0.44
ALDH1A1 P00352 3/20 0.43
HTT P42858 3/20 0.43
MAPT P10636 1/20 0.43
MMP13 P45452 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887064 0.93 MEN1 (0.46) NAMPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL5886891 0.93 TP53 (0.44) HDAC1KMT2AMEN1LMNAALDH1A1
SCHEMBL5886921 0.91 NAMPT (0.43) NAMPTKMT2AMEN1PTGER1LMNA
SCHEMBL5887048 0.89 MAPT (0.42) NAMPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL5887641 0.89 MAPT (0.44) HDAC1KMT2AMEN1LMNAALDH1A1
SCHEMBL5887425 0.89 HTR7 (0.45) KMT2AMEN1LMNAALDH1A1HTT
SCHEMBL5886728 0.88 CTNNB1 (0.48) LMNAMAPTSCD
SCHEMBL5886707 0.88 ALDH1A1 (0.46) LMNAALDH1A1HTTMAPTSMN1; SMN2
SCHEMBL5887548 0.87 KMT2A (0.46) HDAC1KMT2ALMNAALDH1A1MAPT
SCHEMBL5886779 0.87 MAPT (0.44) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP NAMPT 527/4885HDAC3 1305/4885HDAC4 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.